Thermo Fisher Scientific's (TMO) performance has demonstrated notable resilience, achieving seven continuous days of gains with an 8.9% return. Significant progress has been made over the last decade, with a $1000 investment seeing significant increases in value. Analysts are bullish on TMO, recommending it as an oversold stock to buy on several occasions. The company's financial performance has shown an uptick, reporting increased profit and revenue with strong results. Thermo Fisher also announced the FDA's approval of the NGS-based companion diagnostic for Non-Small Cell Lung Cancer Treatment. The stock introduces a unique and exciting opportunity in the Bio-tech market with its ambitious $2 Billion Investment plan, which is expected to further enhance its growth trajectory. However, there has been some fluctuation in the stock's performance with a trade down in Q2. Yet, the company's long-term prospects remain bright, with the recent addition of new microscopes and possible inclusion in large-cap value stocks. The company's strategic partnership with Sanofi continues to expand, enhancing U.S. drug product manufacturing capabilities.
Thermo Fisher Scientific TMO News Analytics from Thu, 30 Jan 2025 08:00:00 GMT to Sat, 16 Aug 2025 05:22:21 GMT -
Rating 7
- Innovation 9
- Information 9
- Rumor -5
